ClinicalTrials.gg
CompletedNCT03437564Updated Jun 27, 2019Results posted

A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets

A Phase 1 interventional study of Vortioxetine in Healthy Adult Participants, sponsored by Takeda. Completed at 1 site in Japan. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-27.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the bioequivalence of a single oral administration of a vortioxetine (Lu AA21004) 20 mg tablet in comparison with two of vortioxetine 10 mg tablets in Japanese healthy adult participants.

Read the detailed description

The drug being tested in this study is called vortioxetine (Lu AA21004). Vortioxetine is being tested in Japanese healthy adult participants. This study will look at the bioequivalence of a single oral administration of a vortioxetine 20 mg tablet in comparison with two of vortioxetine 10 mg tablets, and also look at the safety of a single oral dose of vortioxetine 20 mg in Japanese healthy adult participants.

The study will enroll 28 (14 for each sequence) healthy participants. In case bioequivalence cannot be demonstrated with the number of participants initially planned, an add-on participant study may be conducted (as a maximum 28 participants additionally). Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups.

  • Treatment Group A: Vortioxetine 20 mg (one 20 mg tablet) in Period 1 + Vortioxetine 20 mg (two 10 mg tablets) in Period 2
  • Treatment Group B: Vortioxetine 20 mg (two 10 mg tablets) in Period 1 + Vortioxetine 20 mg (one 20 mg tablet) in Period 2

This single-center trial will be conducted in Japan. The overall time to participate in this study is approximately 25 days. Participants will make two visits to the clinic and be hospitalized for ten days in total.

02

Conditions studied

  • Healthy Adult Participants
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be a healthy Japanese adult volunteer.
  2. Understand the contents of the study and is capable of providing written consent to participate in the study.
  3. Be willing to comply with all study procedures and restrictions.
  4. Aged between ≥20 and ≤45 years at the time of screening.
  5. Have a of ≥18.5 and ≤24.9 (kg/m\^2) and a body weight of ≥50 kg at the time of screening.
  6. Be a extensive metabolizer (EM) based on CYP2D6 genotyping at the time of screening.
  7. A female participant of with a non-sterilized male partner must agree to routinely use appropriate during the study from the time of signing until 4 weeks after last dosing of the study drug.

Exclusion criteria

Exclusion Criteria:

  1. Has received any drug within 90 days before screening for this study.
  2. Previously received Lu AA21004 before participation in this study.
  3. Is an employee of the sponsor or the study site, or immediate family member, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or who may be coerced to provide consent.
  4. Has uncontrolled, neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality which may affect study participation or study results.
  5. Has a history of multiple episodes or severe allergies (eg, food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription drugs, over the counter (OTC) drugs, or foods.
  6. Has a positive pregnancy test at the time of screening or Day -1.
  7. Is a pregnant or lactating female.
  8. Has a positive urine drug screen test at the time of screening or Day -1.
  9. Has a history of drug abuse (defined as any illicit drug use) or has a history of alcohol dependence within 2 years before the start of screening or is unwilling to agree to abstain from alcohol and drugs throughout the study.
  10. Consumes 6 or more servings of caffeinated beverages (containing about 120 mg of caffeine per serving) such as of coffee, tea, cola, or energy drinks.
  11. Is a smoker who smoked cigarettes or used nicotine-containing products (such as nicotine patch) within 6 months before the Period 1 study drug administration.
  12. Used any of the excluded drugs, dietary products or foods during the specified time periods, or will need any of them during the study period.
  13. Has any current or recent gastrointestinal diseases that would be expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once per week] occurrence of heartburn), or any surgical intervention (Stomach, cholecystectomy etc.).
  14. Has a history of cancer.
  15. Has a positive test result for any of the following at the time of screening: surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody/antigen, serological test for syphilis.
  16. Has poor peripheral venous access.
  17. Has undergone whole blood collection of at least 200 mL within 4 weeks (28 days) or at least 400 mL within 12 weeks (84 days) prior to the start of Period 1 study drug administration.
  18. Has undergone whole blood collection of at least 800 mL in total within 52 weeks (364 days) prior to the start of Period 1 study drug administration.
  19. Has undergone blood component collection within 2 weeks (14 days) prior to the start of Period 1 study drug administration.
  20. Has any clinically relevant abnormality in vital signs or 12-lead (ECG) at screening or on Day -1 of Period 1.
  21. Has abnormal laboratory test values at screening or on Day -1 of Period 1 indicating clinically relevant underlying disease, or showing (ALT) and/or aspartate aminotransferase (AST) >1.5× (ULN).
  22. Is unlikely to comply with the protocol requirements or is unsuitable as a participant of this study for any other reason in the opinion of the investigator or sub-investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Vortioxetine one 20 mg tablet + two 10 mg tablets

    Vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.

    Drug: Vortioxetine

  • Experimental
    Vortioxetine two 10 mg tablets + one 20 mg tablet

    Vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.

    Drug: Vortioxetine

Interventions

  • Vortioxetine tablet

    Also known as: Lu AA21004

06

What researchers measure

Primary outcomes

  1. AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

  2. Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

Secondary outcomes

  1. AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

  2. Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

  3. MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

  4. MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

  5. λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

  6. T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004

    Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose

  7. Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)

    Time frame: Up to Day 25

  8. Number of Participants With TEAE Related to Vital Sign

    Time frame: Up to Day 25

  9. Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased)

    Time frame: Up to Day 25

  10. Number of Participants With TEAE Related to 12-lead Electrocardiograms

    Time frame: Up to Day 25

07

Results

Posted Jun 26, 2019

Participant flow

Participants took part in the study at 1 investigative site in Japan, from 16 February 2018 to 13 April 2018.

Participant flow — Overall Study
MilestoneVortioxetine One 20 mg Tablet + Two 10 mg TabletsVortioxetine Two 10 mg Tablets + One 20 mg Tablet
Started1414
Completed1414
Not completed00

Outcome measures

PrimaryAUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · hour*nanogram per milliliter (h*ng/mL)
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004
hour*nanogram per milliliter (h*ng/mL)Vortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004299.3 ± 59.820301.1 ± 62.070
Statistical analysis
  • Vortioxetine One 20 mg Tablet vs Vortioxetine Two 10 mg Tablets · ANOVA · Point estimate: 0.996 · 90% CI 0.967 to 1.026
PrimaryCmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · ng/mL
Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004
ng/mLVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA210048.744 ± 1.78388.976 ± 1.6936
Statistical analysis
  • Vortioxetine One 20 mg Tablet vs Vortioxetine Two 10 mg Tablets · ANOVA · Point estimate: 0.972 · 90% CI 0.937 to 1.008
SecondaryAUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · h*ng/mL
AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004
h*ng/mLVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004463.9 ± 135.58477.6 ± 164.83
SecondaryTmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Median · Hours
Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004
HoursVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA210046.000 (6.00 to 8.00)6.000 (6.00 to 8.00)
SecondaryMRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · Hours
MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004
HoursVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA2100467.27 ± 14.14568.84 ± 18.646
SecondaryMRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · Hours
MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004
HoursVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA2100430.12 ± 1.827430.12 ± 1.8335
Secondaryλz: Apparent Elimination Rate Constant of Unchanged Lu AA21004
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · 1/Hours
λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004
1/HoursVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
λz: Apparent Elimination Rate Constant of Unchanged Lu AA210040.01608 ± 0.00400900.01599 ± 0.0041766
SecondaryT1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004
Time frame:
Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · Hours
T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004
HoursVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA2100445.36 ± 9.769446.44 ± 13.090
SecondaryNumber of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)
Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)10
SecondaryNumber of Participants With TEAE Related to Vital Sign
Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With TEAE Related to Vital Sign
ParticipantsVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
Number of Participants With TEAE Related to Vital Sign00
SecondaryNumber of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased)
Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased)
ParticipantsVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased)10
SecondaryNumber of Participants With TEAE Related to 12-lead Electrocardiograms
Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With TEAE Related to 12-lead Electrocardiograms
ParticipantsVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
Number of Participants With TEAE Related to 12-lead Electrocardiograms00

Adverse events

Collected over Up to Day 25. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine One 20 mg Tablet0/28 (0%)0/28 (0%)1/28 (3.6%)
Vortioxetine Two 10 mg Tablets0/28 (0%)0/28 (0%)0/28 (0%)
Most frequent other events
Most frequent other events
EventVortioxetine One 20 mg TabletVortioxetine Two 10 mg Tablets
Alanine aminotransferase increasedInvestigations1/280/28

Baseline characteristics

Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.

Age, Continuous
Age, Continuous(Years)Vortioxetine One 20 mg Tablet + Two 10 mg TabletsVortioxetine Two 10 mg Tablets + One 20 mg TableTotal
Mean24.0 ± 6.5224.0 ± 4.9624.0 ± 5.68
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine One 20 mg Tablet + Two 10 mg TabletsVortioxetine Two 10 mg Tablets + One 20 mg TableTotal
Female000
Male141428
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Vortioxetine One 20 mg Tablet + Two 10 mg TabletsVortioxetine Two 10 mg Tablets + One 20 mg TableTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Vortioxetine One 20 mg Tablet + Two 10 mg TabletsVortioxetine Two 10 mg Tablets + One 20 mg TableTotal
Japan141428
Height
Height(Centimeters (cm))Vortioxetine One 20 mg Tablet + Two 10 mg TabletsVortioxetine Two 10 mg Tablets + One 20 mg TableTotal
Mean172.4 ± 3.94170.2 ± 6.48171.3 ± 5.38
Weight
Weight(Kilograms (kg))Vortioxetine One 20 mg Tablet + Two 10 mg TabletsVortioxetine Two 10 mg Tablets + One 20 mg TableTotal
Mean63.86 ± 6.69461.91 ± 6.25462.89 ± 6.434
BMI
BMI(kg/meter (m)^2)Vortioxetine One 20 mg Tablet + Two 10 mg TabletsVortioxetine Two 10 mg Tablets + One 20 mg TableTotal
Mean21.46 ± 1.81221.33 ± 1.17521.39 ± 1.500
Smoking Classification
Smoking Classification(Participants)Vortioxetine One 20 mg Tablet + Two 10 mg TabletsVortioxetine Two 10 mg Tablets + One 20 mg TableTotal
Never Smoked121325
Ex-Smoker213

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Nishi Kumamoto Hospital
    Kumamoto, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Apr 2018, 1 month.

Results were first posted in Jun 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2018
First posted
Feb 19, 2018
StartActual
Feb 16, 2018
Primary completionActual
Apr 13, 2018
CompletionActual
Apr 13, 2018
Results first posted
Jun 26, 2019
Last update
Jun 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03437564
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 19, 2018
Start date
Feb 16, 2018
Primary completion
Apr 13, 2018
Completion
Apr 13, 2018
Results posted
Jun 26, 2019
Last update
Jun 27, 2019

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion